CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
BTK 抑制剂治疗后套细胞淋巴瘤：何时 CAR-T 并非答案？
英文原题：Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer?
查看英文原题
Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在一项大型多中心回顾性真实世界分析中，Hess及其同事描述了在brexucabtagene autoleucel（Tecartus）可及之前，在临床实践中管理的post-Bruton酪氨酸激酶抑制剂（BTKi）套细胞淋巴瘤患者的结局。结局数据不仅为未来研究提供了有用的基准，也凸显了在管理这一具有挑战性的患者群体方面仍面临的巨大挑战。评论：Hess et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. Br J Haematol 2023;202:749-759.
展开英文摘要原文
In a large multicentre retrospective real-world analysis, Hess and colleagues describe outcomes in post-Bruton tyrosine kinase inhibitor (BTKi) mantle cell lymphoma patients managed in clinical practice prior to availability of brexucabtagene autoleucel (Tecartus).
Outcome data not only provide a useful benchmark for future studies but also highlight the great challenges that still lie ahead in managing this challenging patient cohort. Commentary on: Hess et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. Br J Haematol 2023;202:749-759.
论文信息
- 作者
- McCulloch R
- 单位
- Department of Haematology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.United Kingdom
- 期刊
- British journal of haematology2023 Aug
- 原文标识
- PubMed 37188352 · DOI 10.1111/bjh.18868